DA Davidson analyst Linda Bolton Weiser keeps her Buy rating and $250 price target on Medifast, saying her discussions with its CFO highlighted the management's confidence in its 2019 guidance. The analyst notes that the company anticipates a re-acceleration of earnings growth in Q4 thanks to the 2% pricing and sequential gross margin lift. Weiser also points to Medifast's new Coach app launches in October in Asia and its roll-out in the U.S. in 2020, which she expects to drive further improvement in productivity that is not currently reflected in her model.